Lenacapavir binding to immature Gag induces giant virions and causes protease-dependent inhibition of viral release
Authors:
- Wright Andrews Ofotsu AmesimekuWAWright Andrews Ofotsu Amesimeku
- Nami MondeNMNami Monde
- Hiromi TerasawaHTHiromi Terasawa
- Hirotaka OdeHOHirotaka Ode
- Hiroyuki SasakiHSHiroyuki Sasaki
- Consolata Elias RukondoCRConsolata Elias Rukondo
- Perpetual NyamePNPerpetual Nyame
- Md. Jakir HossainMHMd. Jakir Hossain
- Akatsuki SaitoASAkatsuki Saito
- Tomohiro SawaTSTomohiro Sawa
Open Access
- 3 September 2026
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (36)
Abstract
Lenacapavir (LEN), a potent capsid inhibitor, suppresses reverse transcription and nuclear import by disrupting capsid core formation in HIV type 1 (HIV-1). However, its effects on late-stage viral assembly remain unclear. Although p24 ELISA suggested that LEN substantially inhibited HIV-1, both RT-dPCR and Vpr-HiBiT assays indicated that suppression of viral release required relatively high LEN concentrations. This discrepancy was attributed to LEN-induced reduction in p24 solubility, leading to an overestimation of its inhibitory effect on viral release. In addition, excessive intracellular Gag processing by the viral protease was observed in the presence of LEN, which contributed to impaired viral release. Furthermore, LEN induced numerous abnormal, discrete clusters of Gag at the plasma membrane. Using mass photometry, which was applied to analyze HIV-1 particle sizes, and transmission electron microscopy, we identified heterogeneous LEN-induced viral-like particles (LENiVLPs; diameter >200 nm) containing both Gag and Env proteins. Although LENiVLPs retained membrane fusion capability, they were noninfectious owing to postentry defects that prevented viral replication. Thus, LEN binds to the precursor Gag and promotes aberrant particle formation, offering insights that could guide the development of next-generation LEN-based therapeutics targeting the late stages of the viral life cycle.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP25fk0410075h0001)
- Japan Agency for Medical Research and Development (JP25fk0410058h0003)
- Japan Agency for Medical Research and Development (JP24fk041047h0003)
- Japan Agency for Medical Research and Development (JP25fk0410056h0003)
- Japan Agency for Medical Research and Development (JP24fk0410058h0001)
- Japan Agency for Medical Research and Development (JP21fk0410026h0001)
- Japan Agency for Medical Research and Development (JP23fk0410058h0001)
- Japan Agency for Medical Research and Development (JP24fk0410065h0001)
- Japan Agency for Medical Research and Development (JP24fk0410058h0202)
- Japan Society for the Promotion of Science London (JP23KK0292)
- Japan Society for the Promotion of Science London (JP23K06561)
- Japan Society for the Promotion of Science London (22K0710)
- Takeda Science Foundation (NA)
- Mitsubishi Foundation (NA)
This publication has 36 references indexed in Scilit:
- A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24Journal of Biological Chemistry, 2024
- Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trialThe Lancet HIV, 2022
- GS-CA1 and lenacapavir stabilize the HIV-1 core and modulate the core interaction with cellular factorsiScience, 2021
- Characterization of Phosphate Buffered Saline (PBS) in Frozen State and after Freeze-DryingPharmaceutical Research, 2019
- Capsid-Dependent Host Factors in HIV-1 InfectionTrends in Microbiology, 2017
- Characterization of a monoclonal anti-capsid antibody that cross-reacts with three major primate lentivirus lineagesVirology, 2012
- Flexible Use of Nuclear Import Pathways by HIV-1Cell Host & Microbe, 2010
- X-Ray Structures of the Hexameric Building Block of the HIV CapsidCell, 2009
- HIV-1 Capsid Protein Forms Spherical (Immature-Like) and Tubular (Mature-Like) Particles in Vitro: Structure Switching by pH-induced Conformational ChangesBiophysical Journal, 2001
- Determination of the size of HIV using adenovirus type 2 as an internal length markerJournal of Virological Methods, 1994